Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

Meng, Fanying, Evans, James W., Bhupathi, Deepthi, Banica, Monica, Lan, Leslie, Lorente, Gustavo, Duan, Jian-Xin, Cai, Xiaohong, Mowday, Alexandra M., Guise, Christopher P., Maroz, Andrej, Anderson, Robert F., Patterson, Adam V., Stachelek, Gregory C., Glazer, Peter M., Matteucci, Mark D., Hart, Charles P. · 2012 · Molecular Cancer Therapeutics

Abstract

TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug (HAP) of bromo-isophosphoramide mustard currently undergoing clinical evaluation. Here, we describe broad-spectrum activity, hypoxia-selective activation, and mechanism of action of TH-302. The concentration and time dependence of TH-302 activation was examined as a function of oxygen concentration, with reference to the prototypic HAP tirapazamine, and showed superior oxygen inhibition of cytotoxicity and much improved dose potency relative to tirapazamine. Enhanced TH-302 cytotoxicity under hypoxia was observed across 32 human cancer cell lines. One-electron reductive enzyme dependence was confirmed using cells overexpressing human NADPH:cytochrome P450 oxidoreductase and radiolytic reduction established the single-electron stoichiometry of TH-302 fragmentation (activation). Examining downstream effects of TH-302 activity, we observed hypoxia-dependent induction of γH2AX phosphorylation, DNA cross-linking, and cell-cycle arrest. We used Chinese hamster ovary cell–based DNA repair mutant cell lines and established that lines deficient in homology-dependent repair, but not lines deficient in base excision, nucleotide excision, or nonhomologous end-joining repair, exhibited marked sensitivity to TH-302 under hypoxia. Consistent with this finding, enhanced sensitivity to TH-302 was also observed in lines deficient in BRCA1, BRCA2, and FANCA. Finally, we characterized TH-302 activity in the three-dimensional tumor spheroid and multicellular layer models. TH-302 showed much enhanced potency in H460 spheroids compared with H460 monolayer cells under normoxia. Multicellular layers composed of mixtures of parental HCT116 cells and HCT116 cells engineered to express an oxygen-insensitive bacterial nitroreductase showed that TH-302 exhibits a significant bystander effect. Mol Cancer Ther; 11(3); 740–51. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-11-0634

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 203

Metadata

Authors
Meng, F., Evans, J. W., Bhupathi, D., Banica, M., Lan, L., Lorente, G., Duan, J.-X., Cai, X., Mowday, A. M., Guise, C. P., Maroz, A., Anderson, R. F., Patterson, A. V., Stachelek, G. C., Glazer, P. M., Matteucci, M. D., & Hart, C. P.
Venue
Molecular Cancer Therapeutics
Published
2012-03-01
Volume
11
Issue
3
Pages
740-751
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2126669622
Cited by
203
References
5
FWCI
13.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302. https://app.cochat.ai/papers/10.1158/1535-7163.mct-11-0634
The paper
Meng, F., Evans, J. W., Bhupathi, D., Banica, M., Lan, L., Lorente, G., Duan, J.-X., Cai, X., Mowday, A. M., Guise, C. P., Maroz, A., Anderson, R. F., Patterson, A. V., Stachelek, G. C., Glazer, P. M., Matteucci, M. D., & Hart, C. P. (2012). Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0634

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.